Creatine for Depression: What the New Research Says

Creatine for Depression: What the New Research Says

Creatine has long been associated with gym bags and protein shakes. But a systematic review published July 8, 2026 in Brain Medicine is adding a more unexpected line to its resume: potential support for people living with major depressive disorder. Here's what the evidence actually shows, and where it still falls short.

What the Systematic Review Found

The review analyzed five randomized controlled trials examining creatine monohydrate supplementation in adults diagnosed with major depressive disorder (MDD). Researchers pooled data across studies to look for patterns in symptom reduction, tolerability, and response rates.

The headline finding: creatine supplementation was associated with measurable reductions in depression symptoms across several of the trials. That's notable on its own. But the more specific finding is what's drawing the most attention from clinicians and researchers.

Women showed significantly greater improvement when creatine was used alongside existing treatments, either antidepressant medication or cognitive behavioral therapy (CBT). The effect wasn't as pronounced when creatine was used as a standalone intervention, and it was less consistent in male participants.

Why might women respond differently? One working hypothesis involves creatine metabolism. Some research suggests women have naturally lower baseline brain creatine levels than men, which could make them more responsive to supplementation. Hormonal fluctuations, particularly around estrogen, may also influence how creatine is processed in the brain. These are hypotheses, not confirmed mechanisms, but they offer a plausible starting point for further investigation.

How Creatine Might Affect the Brain

To understand why creatine is being studied in this context at all, it helps to know what it actually does beyond muscle cells. Creatine plays a central role in energy metabolism by helping regenerate ATP, the molecule your cells use as fuel. The brain is one of the most energy-demanding organs in the body, and disrupted brain energy metabolism has been consistently linked to depression in neuroimaging research.

Several studies using magnetic resonance spectroscopy have found that people with MDD show reduced phosphocreatine levels in the prefrontal cortex, a brain region heavily involved in mood regulation, decision-making, and emotional processing. The logic follows: if depressive states are partly characterized by an energy deficit in specific brain regions, and creatine helps buffer that energy supply, supplementation could theoretically support more stable neurological function.

This isn't a radical idea. Creatine is already being studied for cognitive function, traumatic brain injury recovery, and neurodegenerative conditions. The depression angle is a natural extension of that broader interest in creatine's non-muscular roles.

What the Evidence Does Not Support (Yet)

Five randomized controlled trials is a meaningful start, but it's not a clinical mandate. The authors of the Brain Medicine review are explicit: larger, longer, and more standardized trials are needed before creatine can be recommended as part of any depression treatment protocol.

Several limitations apply to the current body of evidence:

• Sample sizes were small. Most of the included trials had fewer than 100 participants, limiting statistical power and generalizability.
• Dosing varied across studies. Some used 3 grams per day, others used up to 10 grams. There's no established therapeutic dose for depression specifically.
• Trial durations were short. Most interventions ran for eight weeks or less. Depression is a chronic condition for many people, and short trials don't capture long-term dynamics.
• Sex-disaggregated data wasn't always available. The stronger findings in women come from a subset of the trials that reported results by sex. That's not all five studies.
• Study populations weren't uniform. Differences in severity of depression, concurrent treatments, and baseline characteristics make cross-study comparisons complicated.

None of this invalidates the findings. It contextualizes them. Preliminary evidence pointing in a consistent direction is how research is supposed to work before clinical recommendations get made.

Creatine's Safety Profile Makes It Worth Studying Further

One reason researchers are genuinely interested in pursuing this line of investigation is that creatine monohydrate has one of the most well-documented safety profiles of any widely used supplement. Decades of sports science research, and more recent clinical research, consistently find it to be safe and well-tolerated at standard doses (3 to 5 grams per day) in healthy adults.

The most commonly reported side effects are gastrointestinal discomfort and water retention, both of which tend to be mild and dose-dependent. There's no credible evidence linking creatine to kidney or liver damage in people with normal organ function, a concern that used to circulate but has been repeatedly unsupported by the data.

This matters in the context of depression research because adding a low-risk adjunct to existing treatment is a very different risk-benefit calculation than introducing a new pharmaceutical. If creatine turns out to genuinely help, even modestly, the barrier to recommendation is lower than it would be for a drug with a more complex safety profile.

That said, anyone considering creatine supplementation should be talking to a healthcare provider, especially if they're currently on antidepressant medication. Even low-risk supplements interact with clinical care, and self-prescribing based on early-stage research is never a sound strategy. If you want to understand how to evaluate supplement evidence more broadly, Wellness Products: How to Tell Hype From Real Evidence offers a useful framework for thinking critically about these claims.

Where This Fits in the Wider Picture of Creatine Research

This systematic review doesn't exist in isolation. Interest in creatine's neurological effects has been building steadily over the past decade. Researchers have examined it in the context of cognitive performance under sleep deprivation, concussion recovery, and age-related cognitive decline. The emerging picture is of a compound that does more than fuel muscle contractions.

It's also worth noting that the broader supplement space is undergoing a credibility shift. More research is being done on authenticity and quality, with technologies like DNA Testing Is Changing How Supplements Are Made helping verify that what's on the label is actually what's in the bottle. For a compound like creatine, where the research is tied to a specific form (monohydrate) at specific doses, product quality isn't a minor detail.

The mental health dimension is particularly interesting given how much overlap exists between lifestyle factors and mood regulation. Sleep is one obvious example. Research increasingly shows that sleep disturbances both contribute to and result from depression, a relationship recently documented by the APA in a 2026 report. Whether creatine might indirectly support mood by improving sleep quality is an open question the current review doesn't address, but it's the kind of downstream effect that future trials should probably account for.

Should You Start Taking Creatine for Your Mental Health?

Not based on this review alone. That's not a dismissal of the research. It's an honest reading of where the evidence stands.

If you're already taking creatine for physical performance and you happen to notice a mood benefit, that's worth paying attention to and mentioning to your doctor. If you're living with depression and curious about adjunct options, creatine is worth raising as a conversation with your prescriber or therapist, particularly if you're a woman already engaged in antidepressant treatment or CBT.

What you shouldn't do is treat a five-trial systematic review as a prescription. The researchers themselves aren't doing that, and neither should you.

It's also worth keeping the supplement context in mind. Not all creatine products are the same, and the trials in this review used creatine monohydrate specifically. If you're evaluating any supplement, How to Read a Supplement Label Without Getting Fooled is a practical starting point for knowing what you're actually buying.

The Takeaway

The Brain Medicine review is a legitimate contribution to an emerging and genuinely interesting area of research. It adds to a growing body of evidence suggesting creatine has biological effects that extend well beyond muscle tissue, and it raises specific, testable hypotheses about sex differences in treatment response for depression.

It doesn't settle the question. Larger trials, longer interventions, and better-standardized protocols are needed before creatine earns a place in clinical depression guidelines. But the direction of the signal, the biological plausibility, and the established safety profile together make this an area worth watching closely.

For now, the most accurate summary of where the science stands is this: promising, preliminary, and worth taking seriously without overstating what five small trials can actually tell us. That's not a reason to dismiss it. It's a reason to fund the next round of research.